Real‐world use of tirzepatide among individuals without evidence of type 2 diabetes: Results from the Veradigm® database
Majority of individuals in the AOM-eligible cohort had ≥1 ORC, and half had ≥2 ORCs, indicating that in this study cohort tirzepatide was being used in people with multimorbidity. Tirzepatide dose escalation in this real-world cohort was slower than in clinical trials, which may have implications for its real-world effectiveness.
Authors
- Theresa Hunter (ORCID: https://orcid.org/0000-0001-8412-9175)
- Chanadda Chinthammit (ORCID: https://orcid.org/0000-0002-3469-1327)
- Emily R. Hankosky (ORCID: https://orcid.org/0000-0001-9934-584X)
- Jennifer M. Ward
- Robert Sedgley
- Birong Liao (ORCID: https://orcid.org/0000-0002-6336-8940)
- Machaon Bonafede (ORCID: https://orcid.org/0000-0001-6330-6718)
- Katherine Cappell (ORCID: https://orcid.org/0000-0001-9864-4100)
Institutions
- Vera Institute of Justice (US)
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-03-14
- DOI
- https://doi.org/10.1111/dom.16330
- Citations
- 4
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 5.18
Funders
- Eli Lilly and Company